Literature DB >> 6542010

Clinical pharmacokinetics of vindesine: repeated treatments by intravenous bolus injections.

R Rahmani, M Martin, R Favre, J P Cano, J Barbet.   

Abstract

Vindesine was administered intravenously to 12 patients with advanced cancer. Treatment was repeated after 2 weeks or more with a 1.5-to 2-fold increased dose of vindesine. Five patients received one or two additional injections at the higher dose level. One patient was given 0.4, 1 and 4 mg of vindesine on days 1, 3 and 6 and then 8 mg on days 19 and 34. Plasma samples and urine were collected over 3 days after injection and monitored for vindesine by radioimmunoassay. Significant time-dependence of vindesine plasma concentration decay kinetics at a constant dose was observed in four patients out of six. The comparison of the kinetics after administration of different doses to the same patient revealed frequent deviations from linearity with no obvious general trend. Urinary excretion was very low (1-12% of the dose), and urinary excretion rates correlated with plasma concentrations. Renal clearances were variable from one patient to another and also for the same patient from one injection to another. These data were interpreted in terms of time- and dose-dependence of vindesine pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6542010     DOI: 10.1016/0277-5379(84)90061-0

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  5 in total

1.  In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine.

Authors:  X J Zhou; M Martin; M Placidi; J P Cano; R Rahmani
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

2.  In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. I. Vindesine (4-deacetyl-vinblastine 3-carboxyamide).

Authors:  R Rahmani; X J Zhou; M Placidi; M Martin; J P Cano
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

Review 3.  Preclinical and clinical pharmacology of vinca alkaloids.

Authors:  X J Zhou; R Rahmani
Journal:  Drugs       Date:  1992       Impact factor: 9.546

4.  Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods.

Authors:  P Boré; R Rahmani; J van Cantfort; C Focan; J P Cano
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Pharmacokinetics of navelbine after oral administration in cancer patients.

Authors:  X J Zhou; P Boré; S Monjanel; Z Sahnoun; R Favre; A Durand; R Rahmani
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.